Levings Application 3 Flashcards

1
Q

insulin function (3)

A
  • stimulates glucose uptake from blood into tissue
  • stimulates glycogen formation in the liver
  • released from pancreas when blood sugar is high to lower the blood sugar
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

where is insulin produced and by what cell (2)

A
  • produced in pancreatic islets
  • produced by beta cells in islets
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what does the pancreatic islet of a T1D look like (2)

A
  • all beta cells in the islet are destroyed
  • insulin must be obtained exogenously as a result
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

autoimmunity in T1D

A
  • CD8+ T cells specific for islet proteins destroy beta cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

stages of T1D: pre-T1D (3)

A
  • genetic risk
  • immune activation: beta cells are attacked
  • immune response: development of single autoantibody
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

stages of T1D (4)

A
  • stage 1: normal glucose tolerance (more than 2 autoantibodies)
  • stage 2: abnormal glucose tolerance
  • state 3: clinical diagnosis
  • stage 4
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

autoantibodies

A
  • antibodies that target self-tissue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

T1D autoantibodies and lifetime risk

A
  • increased number if islet autoantibodies is correlated with increased lifetime risk of T1D
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

T1D pathogenesis (4)

A
  • APC activates autoreactive CD4+ T cell
  • CD4+ T cell and cytotoxic T lymphocyte go to capillary
  • B cell activation by CD4+ T cell and creation of autoantibodies for islet Ab
  • pancreatic beta cell destruction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

how does immunity to islets go wrong: rare

A
  • single coding mutation in gene essential for central or peripheral tolerance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

example of rare purely genetic cause of T1D (2)

A
  • IPEX syndrome
  • classic triad of dermatitis, T1D, and enteropathy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

how does immunity in islets go wrong: more common

A
  • intersection of genetic susceptibility and an environmental trigger
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

immunity in islets go wrong: genetic susceptibility

A
  • small changes in expression/function of 1+ genes which affect overall function of T cell tolerance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

immunity in islets go wrong: environmental triggers (3)

A
  • prenatal triggers
  • postnatal triggers
  • promoters of progression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

immunity in islets go wrong: environmental triggers examples (2)

A
  • viral trigger (molecular mimicry)
  • microbiome trigger
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

environmental triggers: viral trigger (2)

A
  • viral peptide mimics self peptide
  • APC presents both self and non-self peptide simultaneously
17
Q

environmental triggers: gut microbiota (2)

A
  • intestinal permeability increase or gut microbiota diversity decrease
  • lead to molecular mimicry, inflammation, Treg imbalance, and activate T cells that lead to beta cell destruction
18
Q

proposed mechanism of action of anti-CD3

A
  • alter APC-T cell by partial depleting autoreactive T cells and inducing FOXP3+ Treg cells t0 activate and inhibit autoreactive T cells
19
Q

CD3

A
  • protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell and T helper cells
20
Q

anti-CD3 antibody

A
  • modifies CD8+ lymphocytes to take on T cell unresponsive phenotype
21
Q

problems with anti-CD3 antibody (3)

A
  • flu-like symptoms
  • cross-linking to TCR/CD3 complex, which released cytokines
  • development of anti-mouse antibodies, causing rapid clearance and reduced efficacy
22
Q

development of anti-mouse antibodies: solution

A
  • humanizing antibodies
23
Q

OKT3

A
  • oligomeric and specific chain of CD3 complex
24
Q

teplizumab (3)

A
  • humanized IgG1 antibody
  • developed by grafting complementarity determining region of OKT3 into a human IgG1 backbone
  • two point mutations in Fc portion decrease binding to FcR
25
Q

T cell exhaustion

A
  • persistent antigen following antigen with inhibitory receptor:inhibitory receptor ligand bindings
26
Q

teplizumab effects

A
  • decreases lymphocyte count and increases % of exhausted CD8+ T cells
27
Q

making Tregs from conventional T cells

A
  • gene editing must be done to force FOXP3 expression